FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200504528> ?p ?o ?g. }

• W4200504528 endingPage "256" @default.
• W4200504528 startingPage "245" @default.
• W4200504528 abstract "Abstract Ataxia telangiectasia and Rad3-related (ATR) kinase protects genome integrity during DNA replication. RP-3500 is a novel, orally bioavailable clinical-stage ATR kinase inhibitor (NCT04497116). RP-3500 is highly potent with IC50 values of 1.0 and 0.33 nmol/L in biochemical and cell-based assays, respectively. RP-3500 is highly selective for ATR with 30-fold selectivity over mammalian target of rapamycin (mTOR) and more than 2,000-fold selectivity over ataxia telangiectasia mutated (ATM), DNA-dependent protein kinase (DNA-PK), and phosphatidylinositol 3-kinase alpha (PI3Kα) kinases. In vivo, RP-3500 treatment results in potent single-agent efficacy and/or tumor regression in multiple xenograft models at minimum effective doses (MED) of 5 to 7 mg/kg once daily. Pharmacodynamic assessments validate target engagement, with dose-proportional tumor inhibition of phosphorylated checkpoint kinase 1 (pCHK1) (IC80 = 18.6 nmol/L) and induction of phosphorylated H2A.X variant histone (γH2AX), phosphorylated DNA-PK catalytic subunit (pDNA-PKcs), and phosphorylated KRAB-associated protein 1 (pKAP1). RP-3500 exposure at MED indicates that circulating free plasma levels above the in vivo tumor IC80 for 10 to 12 hours are sufficient for efficacy on a continuous schedule. However, short-duration intermittent (weekly 3 days on/4 days off) dosing schedules as monotherapy or given concomitantly with reduced doses of olaparib or niraparib, maximize tumor growth inhibition while minimizing the impact on red blood cell depletion, emphasizing the reversible nature of erythroid toxicity with RP-3500 and demonstrating superior efficacy compared with sequential treatment. These results provide a strong preclinical rationale to support ongoing clinical investigation of the novel ATR inhibitor, RP-3500, on an intermittent schedule as a monotherapy and in combination with PARP inhibitors as a potential means of maximizing clinical benefit." @default.
• W4200504528 created "2021-12-31" @default.
• W4200504528 creator A5001070298 @default.
• W4200504528 creator A5004724371 @default.
• W4200504528 creator A5005745753 @default.
• W4200504528 creator A5006536921 @default.
• W4200504528 creator A5007942593 @default.
• W4200504528 creator A5009355257 @default.
• W4200504528 creator A5021752522 @default.
• W4200504528 creator A5023693476 @default.
• W4200504528 creator A5025547024 @default.
• W4200504528 creator A5026092257 @default.
• W4200504528 creator A5027475930 @default.
• W4200504528 creator A5033446729 @default.
• W4200504528 creator A5034752648 @default.
• W4200504528 creator A5035113968 @default.
• W4200504528 creator A5038266366 @default.
• W4200504528 creator A5039168292 @default.
• W4200504528 creator A5040084790 @default.
• W4200504528 creator A5042263577 @default.
• W4200504528 creator A5042914447 @default.
• W4200504528 creator A5046763171 @default.
• W4200504528 creator A5048516275 @default.
• W4200504528 creator A5052089228 @default.
• W4200504528 creator A5056470194 @default.
• W4200504528 creator A5063840599 @default.
• W4200504528 creator A5067701795 @default.
• W4200504528 creator A5074475804 @default.
• W4200504528 creator A5084055397 @default.
• W4200504528 creator A5086600866 @default.
• W4200504528 creator A5089906729 @default.
• W4200504528 date "2021-12-15" @default.
• W4200504528 modified "2023-10-14" @default.
• W4200504528 title "RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors" @default.
• W4200504528 cites W1855851918 @default.
• W4200504528 cites W1984373702 @default.
• W4200504528 cites W2002143632 @default.
• W4200504528 cites W2022529631 @default.
• W4200504528 cites W2046216305 @default.
• W4200504528 cites W2074446011 @default.
• W4200504528 cites W2100681150 @default.
• W4200504528 cites W2105766695 @default.
• W4200504528 cites W2106018842 @default.
• W4200504528 cites W2145747268 @default.
• W4200504528 cites W2201979800 @default.
• W4200504528 cites W2333415105 @default.
• W4200504528 cites W2561432266 @default.
• W4200504528 cites W2594301310 @default.
• W4200504528 cites W2605336808 @default.
• W4200504528 cites W2625452721 @default.
• W4200504528 cites W2775990711 @default.
• W4200504528 cites W2784131712 @default.
• W4200504528 cites W2805040559 @default.
• W4200504528 cites W2808161922 @default.
• W4200504528 cites W2810414233 @default.
• W4200504528 cites W2886880700 @default.
• W4200504528 cites W2888068269 @default.
• W4200504528 cites W2897726163 @default.
• W4200504528 cites W2898088739 @default.
• W4200504528 cites W2900056609 @default.
• W4200504528 cites W2905255940 @default.
• W4200504528 cites W2911653212 @default.
• W4200504528 cites W2936141205 @default.
• W4200504528 cites W2944727022 @default.
• W4200504528 cites W2945986243 @default.
• W4200504528 cites W2949415937 @default.
• W4200504528 cites W2954828350 @default.
• W4200504528 cites W2972107575 @default.
• W4200504528 cites W2972572345 @default.
• W4200504528 cites W2972789187 @default.
• W4200504528 cites W2974169603 @default.
• W4200504528 cites W2978188039 @default.
• W4200504528 cites W2978929492 @default.
• W4200504528 cites W2994057850 @default.
• W4200504528 cites W3027186100 @default.
• W4200504528 cites W3034290849 @default.
• W4200504528 cites W3036123907 @default.
• W4200504528 cites W3044025582 @default.
• W4200504528 cites W3089375288 @default.
• W4200504528 cites W3092288940 @default.
• W4200504528 cites W3154101159 @default.
• W4200504528 cites W3164636335 @default.
• W4200504528 cites W3171548871 @default.
• W4200504528 cites W4238830004 @default.
• W4200504528 cites W639927575 @default.
• W4200504528 doi "https://doi.org/10.1158/1535-7163.mct-21-0615" @default.
• W4200504528 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34911817" @default.
• W4200504528 hasPublicationYear "2021" @default.
• W4200504528 type Work @default.
• W4200504528 citedByCount "32" @default.
• W4200504528 countsByYear W42005045282021 @default.
• W4200504528 countsByYear W42005045282022 @default.
• W4200504528 countsByYear W42005045282023 @default.
• W4200504528 crossrefType "journal-article" @default.
• W4200504528 hasAuthorship W4200504528A5001070298 @default.
• W4200504528 hasAuthorship W4200504528A5004724371 @default.
• W4200504528 hasAuthorship W4200504528A5005745753 @default.
• W4200504528 hasAuthorship W4200504528A5006536921 @default.

• next